Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $43

Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $44 to $43.